Videos
Considerations for Immunotherapy Rechallenge in Esophageal and Gastric Cancers
03/17/2026
At Great Debates Solid Tumors in Miami, Florida, Rutika Mehta, MD, from Weill Cornell Medicine, New York, New York, discusses whether immunotherapy rechallenge should be considered for patients with esophageal and gastric cancers.
Dr Mehta discusses how earlier use of immunotherapy creates opportunities for rechallenge later in treatment and highlights factors such as response depth, durability, and ctDNA dynamics that may help guide these decisions.
Source:
Mehta R. IO rechallenge in esophageal and gastric cancers: Balancing safety concerns vs potential benefit or reinitiation. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
